Sernova Biotherapeutics Inc SVA
TSX · Canada · Health Technology
CAD 0.1100+0.01 (+4.76%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement PlatformTORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a clinical-stage regenerative medicine company focused on developing cell therapies with the goal of delivering a functional cure for type 1 diabetes (T1D), today announced Sernova and Serax
Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection with Seraxis's proposal ("Proposed Transaction") to acquire all of the securities of Sernova Biotherapeutics Inc. ("Sernova") pursuant to an arrangement agreement dated September 7, 2026 between Seraxis and Sernova ("Arrangement Agreement"). Pursuant to the Arrangement Agreement, holders of.
Jonathan Rigby, CEO of Sernova and Will Rust, Ph.D., CEO of Seraxis to Present Merger Details to Form BetaNova Biotherapeutics, a Differentiated Leader in Type1 Diabetes Cell TherapyTORONTO and GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced it will be participatin
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.